MCID: CHL033
MIFTS: 31

Childhood Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Childhood Malignant Schwannoma

MalaCards integrated aliases for Childhood Malignant Schwannoma:

Name: Childhood Malignant Schwannoma 12 15
Childhood Neurofibrosarcoma 74
Pediatric Mpnst 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7732
NCIt 51 C8094
UMLS 74 C0279987

Summaries for Childhood Malignant Schwannoma

MalaCards based summary : Childhood Malignant Schwannoma, also known as childhood neurofibrosarcoma, is related to keratocystic odontogenic tumor and malignant pleural mesothelioma. An important gene associated with Childhood Malignant Schwannoma is BIRC5 (Baculoviral IAP Repeat Containing 5), and among its related pathways/superpathways are Signaling by GPCR and Cytokine Signaling in Immune system. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are cellular and hematopoietic system

Related Diseases for Childhood Malignant Schwannoma

Diseases related to Childhood Malignant Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 keratocystic odontogenic tumor 10.0 BIRC5 CCND1
2 malignant pleural mesothelioma 9.9 BIRC5 SPP1
3 atypical teratoid rhabdoid tumor 9.9 CCND1 SPP1
4 osteofibrous dysplasia 9.9 NF1 SPP1
5 gastrointestinal stromal tumor 9.8 CCND1 NF1
6 von hippel-lindau syndrome 9.7 CCND1 NF1
7 adamantinoma of long bones 9.7 BIRC5 CCND1 SPP1
8 nervous system cancer 9.6 CCND1 NF1

Graphical network of the top 20 diseases related to Childhood Malignant Schwannoma:



Diseases related to Childhood Malignant Schwannoma

Symptoms & Phenotypes for Childhood Malignant Schwannoma

MGI Mouse Phenotypes related to Childhood Malignant Schwannoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.88 BIRC5 CCND1 FN1 NF1 SPP1
2 hematopoietic system MP:0005397 9.83 BIRC5 CCND1 FN1 NF1 SPP1
3 homeostasis/metabolism MP:0005376 9.8 BIRC5 CCND1 FN1 NF1 SPP1
4 immune system MP:0005387 9.77 BIRC5 CCND1 FN1 NF1 SPP1
5 craniofacial MP:0005382 9.76 CCND1 FN1 NF1 SPP1
6 mortality/aging MP:0010768 9.65 BIRC5 CCND1 FN1 NF1 SPP1
7 integument MP:0010771 9.62 CCND1 FN1 NF1 SPP1
8 neoplasm MP:0002006 9.46 CCND1 FN1 NF1 SPP1
9 normal MP:0002873 9.26 BIRC5 CCND1 FN1 NF1
10 skeleton MP:0005390 8.92 CCND1 FN1 NF1 SPP1

Drugs & Therapeutics for Childhood Malignant Schwannoma

Drugs for Childhood Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18
Isophosphamide mustard Phase 3,Phase 2 0
19 Nucleic Acid Synthesis Inhibitors Phase 3
20 Immunologic Factors Phase 3,Phase 2
21 Etoposide phosphate Phase 3,Phase 2
22 Antirheumatic Agents Phase 3,Phase 1
23 Antimitotic Agents Phase 3
24 Anti-Infective Agents Phase 3,Phase 2
25 Immunosuppressive Agents Phase 3,Phase 2
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
27 Histamine Antagonists Phase 3
28 Neurotransmitter Agents Phase 3
29 Gastrointestinal Agents Phase 3
30 Serotonin Agents Phase 3
31 Serotonin Antagonists Phase 3
32 Anti-Allergic Agents Phase 3
33 Antipruritics Phase 3
34 Dermatologic Agents Phase 3
35 Histamine H1 Antagonists Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
41
Lenograstim Approved, Investigational Phase 2 135968-09-1
42 Antibodies, Monoclonal Phase 2,Phase 1
43 Immunoglobulins Phase 2,Phase 1
44 Antifungal Agents Phase 2
45 Antibodies Phase 2,Phase 1
46 Adjuvants, Immunologic Phase 2
47 Protein Kinase Inhibitors Phase 2
48 Imatinib Mesylate Phase 2 220127-57-1 123596
49
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
50 Anti-Inflammatory Agents Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
6 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
7 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
8 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
9 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
10 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
11 Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Completed NCT00003793
12 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 Not Applicable glutamine

Search NIH Clinical Center for Childhood Malignant Schwannoma

Genetic Tests for Childhood Malignant Schwannoma

Anatomical Context for Childhood Malignant Schwannoma

MalaCards organs/tissues related to Childhood Malignant Schwannoma:

42
Bone

Publications for Childhood Malignant Schwannoma

Variations for Childhood Malignant Schwannoma

Expression for Childhood Malignant Schwannoma

Search GEO for disease gene expression data for Childhood Malignant Schwannoma.

Pathways for Childhood Malignant Schwannoma

Pathways related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 BIRC5 CCND1 FN1 NF1 SPP1
2
Show member pathways
12.73 BIRC5 CCND1 FN1 NF1
3
Show member pathways
12.56 CCND1 FN1 SPP1
4
Show member pathways
12.44 CCND1 FN1 SPP1
5 12.38 BIRC5 CCND1 FN1
6 11.8 BIRC5 CCND1
7 11.79 CCND1 NF1
8
Show member pathways
11.79 FN1 SPP1
9 11.73 CCND1 SPP1
10
Show member pathways
11.72 FN1 NF1
11 11.7 CCND1 FN1
12
Show member pathways
11.67 CCND1 NF1
13 11.58 CCND1 NF1
14 11.52 CCND1 FN1
15 11.48 CCND1 FN1
16
Show member pathways
11.26 BIRC5 CCND1
17 11.17 CCND1 NF1
18 11.11 BIRC5 CCND1
19 11.03 FN1 SPP1
20 10.86 BIRC5 CCND1 FN1
21 10.85 CCND1 SPP1
22 10.72 BIRC5 CCND1
23 10.47 FN1 NF1

GO Terms for Childhood Malignant Schwannoma

Biological processes related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 osteoblast differentiation GO:0001649 9.43 NF1 SPP1
2 positive regulation of cell proliferation GO:0008284 9.43 BIRC5 CCND1 FN1
3 wound healing GO:0042060 9.4 FN1 NF1
4 response to organic substance GO:0010033 9.37 CCND1 SPP1
5 liver development GO:0001889 9.32 CCND1 NF1
6 response to steroid hormone GO:0048545 9.16 CCND1 SPP1
7 cytokine-mediated signaling pathway GO:0019221 9.13 BIRC5 CCND1 FN1
8 extracellular matrix organization GO:0030198 8.8 FN1 NF1 SPP1

Molecular functions related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 8.96 BIRC5 FN1
2 enzyme binding GO:0019899 8.8 BIRC5 CCND1 FN1

Sources for Childhood Malignant Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....